Biden Administration details inadequate protection of American intellectual property and foreign barriers to innovation abroad

More than two years into the COVID-19 pandemic, the world has witnessed the immense value of biopharmaceutical innovation. With numerous safe and effective vaccines and treatments developed in record...
Read More
PhRMA encourages Biden administration to pursue ambitious Indo-Pacific Economic Framework

Last fall, President Biden announced that the United States would explore development of an Indo-Pacific Economic Framework (IPEF) to deepen economic relations in the region and collaborate to...
Read More
Research and development continues long after a medicine is initially approved

The government’s flawed price setting plan under the Build Back Better Act will significantly upend the biopharmaceutical research and development (R&D) process, risking important advances in patient...
Read More
Protecting U.S. innovation abroad to support economic and pandemic recovery

PhRMA’s recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2022 Special 301 Report reinforce how the United States can confirm its strong commitment to defend...
Read More
Legislation threatens patent protections and future innovation

Recently introduced legislation, the “Restoring the America Invents Act (RAIA),” if enacted, would push the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office to grant more...
Read More
Global COVID-19 vaccination matters now and for the future

Recently, I joined a panel at the Aspen Security Forum to discuss how we can best get vaccines in arms around the globe as we fight COVID-19. As I noted during my remarks, the world is more...
Read More
New report highlights importance of IP-intensive manufacturing industries to the U.S. economy

A new report from NDP Analytics showcases how innovation is the lifeblood of economic growth in the United States and that intellectual property (IP) protections are a crucial driver for high rates...
Read More
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19 and other diseases

The biopharmaceutical industry has been working tirelessly to develop and manufacture innovative vaccines, therapies and diagnostics to combat COVID-19 and other diseases and illnesses. As of October...
Read More
Patients and innovators lose if the government pursues ‘march-in’

The Biden Administration this summer issued an executive order that seems to endorse the use of “march-in” – when the government seizes patent rights from an innovator to let competitors use that...
Read More
Supporting country readiness to boost global vaccine access

The following is part of a series of posts detailing each of the five strategies to advance global COVID-19 vaccine equity – which rely on and benefit from a strong intellectual property ecosystem.
Read More